Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings

CareDx (CDNA) reported Q2 2025 revenue of $86.68 million and EPS of $0.10, significantly missing consensus estimates by 4.45% and 16.67% respectively, and showing year-over-year declines from $0.25 EPS and $92.31 million revenue. The revenue miss was primarily driven by a 12.5% year-over-year decline in its largest segment, Testing Services, despite growth in Patient and Digital Solutions and Product revenues. The stock has underperformed, dropping 33.3% over the past month compared to the S&P 500's 0.5% gain, reflecting investor reaction to the disappointing results.

Analysis

CareDx (CDNA) reported a challenging second quarter for 2025, with significant misses on both revenue and earnings per share against Wall Street consensus. Total revenue of $86.68 million marked a 6.1% year-over-year decline and fell 4.45% short of the $90.72 million estimate. The bottom-line performance was weaker, as the reported EPS of $0.10 was a substantial drop from $0.25 in the prior-year period and missed the consensus estimate of $0.12 by 16.67%. The primary driver for this underperformance was the company's largest segment, Testing Services, which saw revenue shrink by 12.5% year-over-year to $62.03 million, well below analyst expectations. In contrast, the smaller segments showed notable strength; Patient and Digital Solutions revenue grew 19.2% and Product revenue increased 11.5%, with both exceeding analyst forecasts. This mixed-signal performance has been met with a strongly negative market reaction, evidenced by the stock's 33.3% decline over the past month, a stark underperformance compared to the S&P 500's modest 0.5% gain.

Key Decisions for Investors

• Investors should be cautious given the significant revenue and earnings miss, driven by a 12.5% year-over-year decline in the company's largest segment, Testing Services.
• The strong double-digit growth in the smaller 'Patient and digital solutions' and 'Product' segments should be monitored to see if they can scale sufficiently to offset the weakness in the core business over the coming quarters.
• Considering the stock's recent 33.3% plunge and its current Zacks Rank of #3 (Hold), investors may find it prudent to wait for signs of stabilization or a turnaround in the Testing Services segment before initiating or adding to a position.